Resverlogix Announces Dr. H. Bryan Brewer Joins Clinical Steering Committee

June 23, 2011

CALGARY, June 23, 2011 /PRNewswire/ – Mr. Don McCaffrey, President and CEO of
Resverlogix Corp. (TSX:RVX) is pleased to announce today the addition
of Professor H. Bryan Brewer to Resverlogix’s Clinical Steering
Committee.  Professor Brewer, a cardiologist, is currently the Director
of Lipoprotein and Atherosclerosis Research, Cardiovascular Research
Institute, Washington Hospital Center, Washington, D.C., USA. 
Professor Brewer was the former Chief of the Molecular Disease Branch
at the National Institute of Health, Bethesda, MD, USA and is a leader
and pioneer in the field of high density lipoprotein (HDL) research. 
His seminal observations led to the cloning of the Apolipoprotein A-I
(ApoA-I) mRNA and the gene.  The availability of the ApoA-I mRNA and
gene enabled clinicians and scientists to understand the role of ApoA-I
protein in reverse cholesterol transport (RCT) and atherosclerosis

“Professor Brewer is one of the most well respected pioneers in the
field of HDL biology.  He has extensive industry expertise having
served as a consultant to major pharmaceutical companies including
Abbott, Lilly, Merck, Pfizer, Roche, Sanofi-Aventis and
Schering-Plough.  These skills will enhance the activities of our
Clinical Steering Committee which is instrumental in the design and
conduct of Resverlogix’s human clinical trials relating to its lead
compound RVX-208,” said Mr. McCaffrey. 

Dr. Jan Johansson, Senior Vice President of Medical Affairs of
Resverlogix stated, “Dr. Brewer’s joining our Clinical Steering
Committee further validates RVX-208′s unique position in the critically
important atherosclerosis market. Our highly differentiated mechanism
in HDL biology, the raising of ApoA-I production and enhancement of RCT
biomarkers, is seen by many as the most logical approach to harness the
benefits of RCT and provide efficient reduction of atherosclerosis
burden from coronary arteries. If our lead drug RVX-208 can facilitate
this type of effect in high risk CVD patients in only 26 weeks it will
be positioned as a new breakthrough treatment for millions of patients
around the world”.

The Company has gained valuable insight from the recently completed
Phase 2 ASSERT trial. The important knowledge from ASSERT enabled us to
identify and target high-risk patients for the next trial of RVX-208
called ASSURE.  The Phase 2b ASSURE trial will target high-risk CVD
patients who have low HDL.  The AHA 2010 report states that more than
35 million American adults have low HDL. ASSURE is the first Phase 2b
clinical trial lasting 26 weeks to examine a novel small molecule,
RVX-208, that enhances ApoA-I production in CVD patients with low HDL. 
In ASSURE, intravascular ultrasound (IVUS) will be used to measure
changes in coronary atherosclerosis as the primary endpoint, while
measures of RCT biomarkers will serve as secondary endpoints.

About RVX-208
RVX-208, a small molecule therapeutic that stimulates endogenous ApoA-I
production, is positioned to be one of the emerging drugs that holds
most promise in the treatment of atherosclerosis. To the Company’s
knowledge RVX-208 is the only orally active small molecule that
selectively stimulates ApoA-I production to increase levels of HDL. 
The use of this approach will enhance HDL functionality in mediating
reverse cholesterol transport (RCT). RCT is a pathway by which
cholesterol that has accumulated in atherosclerotic plaques within the
arterial wall can be transported to the liver for excretion, thus
stabilizing, reducing or preventing atherosclerosis disease conditions.

About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets
with significant unmet medical needs. The NexVas(TM) PR program is the
Company’s primary focus which is to develop novel small molecules that
enhance ApoA-I production. These vital therapies are focused to address
the burden of atherosclerosis and other important diseases such as
Acute Coronary Syndrome, Diabetes, Alzheimer’s disease, Peripheral
Artery Disease and other vascular disorders. Resverlogix Corp.’s common
shares trade on the Toronto Stock Exchange (TSX:RVX). For further
information please visit www.resverlogix.com.

This news release may contain certain forward-looking information as
defined under applicable Canadian securities legislation, including our
statements with respect to research, development and commercialization
of novel therapeutics that reduce the risk of cardiovascular disease
including atherosclerosis, Diabetes, Alzheimer’s disease, Peripheral
Artery Disease and other vascular diseases that are not based on
historical fact, including without limitation statements containing the
words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”,
“expects”, “continue”, “estimate”, “forecasts” and other similar
expressions. Our actual results, events or developments could be
materially different from those expressed or implied by these
forward-looking statements. We can give no assurance that any of the
events or expectations will occur or be realized. By their nature,
forward-looking statements are subject to numerous known and unknown
risks and uncertainties including but not limited to those risk factors
discussed in the Company’s Annual Information Form and January 31, 2011
MD&A which are incorporated herein by reference and other documents we
file from time to time with securities authorities, which are available
through SEDAR at www.sedar.com. The forward-looking statements
contained in this news release are expressly qualified by this
cautionary statement and are made as of the date hereof. The Company
disclaims any intention and has no obligation or responsibility, except
as required by law, to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise. The
TSX Exchange does not accept responsibility for the adequacy or
accuracy of this news release.

SOURCE Resverlogix Corp.

Source: newswire

comments powered by Disqus